2024年发表论文：

1. Man XY, Li WJ, Zhu MH, Li SH, Xu G, Zhang ZL, Yang F*, Liang H*. Anticancer tetranuclear Cu(I) complex catalyzes a click reaction to synthesize a chemotherapeutic agent in situ to achieve targeted dual-agent combination therapy for cancer. Angewandte Chemie-International Edition, 2024, e202411846. DOI:10.1002/anie.202411846.

2. Xu G, Liang QY, Gao LJ, Xu SH, Luo WC, Wu QM, Li JY, Zhang ZL, Liang H, Yang F*. Developing an arene bi-nuclear ruthenium(II) complex to induce ferroptosis and activate the cGAS-STING pathway: targeted inhibiting growth and metastasis of triple negative breast cancer. Journal of Medicinal Chemistry, 2024, 67, 10.1021/acs.jmedchem.4c01908.

3. Li WJ, Li SH, Zhu MH, Xu G, Man XY, Zhang ZL, Liang H*, Yang F*. Developing a rhodium(III) complex to reprogram the tumor immune and metabolic microenvironments: overcoming multidrug resistance and metastasis in non-small cell lung cancer. Journal of Medicinal Chemistry, 2024, DOI: 10.1021/acs.jmedchem.4c01133.

4. Jiang M, Li WJ, Liang JZ, Pang M, Li SH, Xu G, Zhu MH, Liang H, Zhang ZL*, Yang F*. Developing a palladium(II) agent to overcome multi-drug resistance and metastasis of liver tumor by targeted multi-acting on tumor cell, inactivating cancer-associated fibroblast and activating immune response. Journal of Medicinal Chemistry, 2024, 67, 16296–16310.

5. Man XY, Li WJ, Zhu MH, Li SH, Xu G, Zhang ZL, Liang H*, Yang F*. Rational design of a hetero-multinuclear gadolinium(III)-copper(II) complex: integrating magnetic resonance imaging, photoacoustic imaging, mild photothermal therapy, chemotherapy and immunotherapy of cancer. Journal of Medicinal Chemistry, 2024, 67, 15606–15619.

6. Man XY, Li SH, Xu G, Li WJ, Zhu MH, Zhang ZL, Liang H*, Yang F*. Developing a copper(II) isopropyl 2-pyridyl ketone thiosemicarbazone compound based on the IB subdomain of human serum albumin–indomethacin complex: inhibiting tumor growth by remodeling the tumor microenvironment. Journal of Medicinal Chemistry, 2024, 67, 5744–5757.

7. Li WJ, Li T, Pan Y, Li SH, Xu G, Zhang ZL, Liang H*, Yang F*. Designing a mitochondria-targeted theranostic cyclometalated iridium(Ⅲ) complex: Overcoming cisplatin resistance and inhibiting tumor metastasis through necroptosis and immune response. Journal of Medicinal Chemistry, 2024, 67, 3843–3859.

8. Man XY, Zhu MH, Li SH, Li WJ, Xu G, Zhang ZL, Wu XY, Liang H*, Yang F*. Design of a theranostic Gd(III)–Cu(I) complex to inhibit the growth and metastasis of triple-negative breast cancer through mitochondria-mediated apoptosis and cancer stem cell inhibition. Rare Metals, 2024, Accepted.

9. Li WJ, Li SH, Man XY, Xu G, Zhang ZL, Zhang Yao, Liang H*, Yang F*. Designing a novel Au(III) agent to inhibit tumor growth and metastasis through immunogenic cell death induced by combination of endoplasmic reticulum stress and mitochondrial dysfunction. Rare Metals, 2024, https://doi.org/10.1007/s12598-024-02871-x.

10. Man XY, Sun ZW, Li SH, Xu G, Li WJ, Zhang ZL, Liang H*, Yang F*. Development of a platinum(II) compound based on indocyanine green@human serum albumin nanoparticles: integrating phototherapy, chemotherapy, and immunotherapy to overcome tumor cisplatin resistance. Rare Metals, 2024, https://doi.org/10.1007/s12598-024-02759-w.

11. Xu SH, Luo WC, Zhu MH, Zhao L, Gao LJ, Liang H, Zhang ZL*, Yang F*. Human serum albumin-platinum(II) agent nanoparticles inhibit tumor growth through multi-modal action against tumor microenvironment. Molecular Pharmaceutics, 2024, 21: 346–357.

12. Wang XJ, Zhu MH, Li SH, Xu G, Zhang ZL*, Yang F*. Novel mono-, bi-, tri- and tetra-nuclear copper complexes that inhibit tumor growth through apoptosis and anti-angiogenesis. Journal of Inorganic Biochemistry, 2024, 250, 112403.

13. Jia XY, Pang JH, Chu Y, Li SH, Li WJ, Jiang M*, Yang F*. In vitro and In vivo anticancer activities of Bi(III) 2-thiazolecarboxaldehyde thiosemicarbazone complex. Journal of Molecular Structure, 2024, 1318, 139389.

2023年发表论文：

1. Zhu MH, Man XY, Yang TF, Li WJ, Li SH, Xu G, Zhang ZL, Liang H*, Yang F*. Developing a hetero-trinuclear erbium(III)-copper(II) complex based on apoferritin: targeted photoacoustic imaging and multi-modality therapy of tumor. Journal of Medicinal Chemistry, 2023, 66, 15424−15436.

2. Li WJ, Li SH, Xu G, Man XY, Yang TF, Zhang ZL, Liang H*, Yang F*. Developing a ruthenium(III) complex to trigger gasdermin E-mediated pyroptosis and immune response based on decitabine and liposomes: targeting inhibition of gastric tumor growth and metastasis. Journal of Medicinal Chemistry, 2023, 66, 13072–13085.

3. Li WJ, Li SH, Zhang ZL, Xu G, Man XY, Yang F*, Liang H*. Developing a multi-targeted anticancer palladium(II) agent based on the His-242 residue in IIA subdomain of human serum albumin. Journal of Medicinal Chemistry, 2023, 66, 8564–8579.

4. Man XY, Yang TF, Li WJ, Li SH, Xu G, Zhang ZL, Liang H*, Yang F*. Developing a gadolinium(III) compound based on apoferritin for targeted magnetic resonance imaging and dual-modal therapy of cancer. Journal of Medicinal Chemistry, 2023, 66: 7268–7279.

5. Zhang ZL, Zhang JZ, Yang TF, Li SH, Xu G, Liang H*, Yang F*. Developing an anticancer platinum(II) compound based on the uniqueness of human serum albumin. Journal of Medicinal Chemistry, 2023, 66: 5669–5684.

6. Yang TF, Zhang ZL, Zhang JZ, Li YP, Li WJ, Liang H*, Yang F*. Developing a gallium(III) agent based on properties of the tumor micro-environment and lactoferrin: Achieving two-agent co-delivery and multi-targeted combination therapy of cancer. Journal of Medicinal Chemistry, 2023, 66: 793−803.

7. Deng JG, Wu YR, Li AL, Pan WP, Hou LX, Wu DQ, Zhang ZL, Yang F*, Gou Y*. Dithiocarbazate–Zn(II) complexes for photodynamic therapy and chemotherapy against lung cancer. Inorganic Chemistry Frontiers, 2023, 10: 6526−6536.

8. Zhang J, Fang R, Li Y, Jin J, Yang F*, Chen J*. Encapsulation of Au(III) complex using lactoferrin nanoparticles to combat glioma. Molecular Pharmaceutics, 2023, 20, 3632–3644.

9. Jiang M, Zhang JZ, Xu SH, Li YP, Li WJ, Liang H, Yang F*. Designing a multitarget In(III) compound to overcome the resistance of lung cancer cells to cisplatin. Dalton Transactions, 2023, 52: 269−280.

10. Jiang M, Pang JH, Jia XY, Chu Y, Li WJ, Liang H, Yang F*. Development of zinc(II) 2-pyridinecarboxaldehyde thiosemicarbazone complex with remarkable antitumor and antiangiogenic activities. Dalton Transactions, 2023, 52: 6029−6040.

2022年发表论文：

1. Zhang ZL, Yang TF, Zhang JZ, Li WJ, Li SH, Sun HB, Liang H*, Yang F*. Developing a novel indium(III) agent based on human serum albumin nanoparticles: integrating bioimaging and therapy. Journal of Medicinal Chemistry, 2022, 65: 5392−5406. 

2. Jiang M, Zhang ZL, Li WJ, Man XY, Sun HB, Liang H*, Yang F*. Developing a copper(II) agent based on His-146 and His-242 residues of human serum albumin nanoparticles: integration to overcome cisplatin resistance and inhibit the metastasis of nonsmall cell lung cancer. Journal of Medicinal Chemistry, 2022, 65: 9447−9458.

3. Gou Y, Jia XY, Hou LX, Deng JG, Huang GJ, Jiang HW*, Yang F*. Dithiocarbazate−Fe III , −Co III , −Ni II , and −Zn II complexes: design, synthesis, structure, and anticancer evaluation. Journal of Medicinal Chemistry, 2022, 65: 6677−6689.

4. Jiang M, Yang TF, Chu Y, Zhang ZL, Sun HB, Liang H, Yang F*. Design of a novel Pt(II) complex to reverse cisplatin-induced resistance in lung cancer via a multi-mechanism. Dalton Transactions, 2022, 51: 5257−5270.

5. Zhang JZ, Li YP, Fang RH, Wei W, Wang Y, Jin JM, Yang F*, Chen J*. Organometallic gold(I) and gold(III) complexes for lung cancer treatment. Frontiers in Pharmacology, 2022, 13: 979951.

2021年发表论文：

1. Gou Y, Huang GJ, Li JL, Yang F*, Liang H*. Versatile deliverysystems for non-platinum metal-based anticancer therapeutic agents. Coordination Chemistry Reviews, 2021, 441: 213975. 

2. Jiang M, Chu Y, Yang TF, Li WJ, Zhang ZL, Sun HB, Liang H*, Yang F*. Developing a novel indium(III) agent based on liposomes to overcome cisplatin-induced resistance in breast cancer by multitargeting the tumor microenvironment components. Journal of Medicinal Chemistry, 2021, 64: 14587−14602.

3. Zhang JZ, Jiang M, Li SH, Zhang ZL, Sun HB, Yang F*,Liang H*. Developing a novel anticancer gold(III) agent to integrate chemotherapyand immunotherapy. Journal of Medicinal Chemistry, 2021, 64: 6777−6791.

4. Gou Y, Chen MR, Li SH, Deng JG, Li JL, Fang GH, Yang F*, Huang GJ*. Dithiocarbazate-copper complexes for bioimaging and treatment of pancreaticcancer. Journal of Medicinal Chemistry, 2021, 64: 5485−5499.

5. Wu JM, Yang TF, Wang XJ, Li WJ, Pang M, Sun HB, Liang H*, Yang F*. Development of a multi-target anticancer Sn(II) pyridine-2-carboxaldehyde thiosemicarbazone complex. Dalton Transactions, 2021, 50: 10909−10921.

6. Jiang M, Li SH, Wu JM, Li WJ, Wen X, Liang H, Yang F*. Designing biotin-human serum albumin nanoparticles to enhance the targeting ability of binuclear ruthenium(III) compound. Journal of Inorganic Biochemistry, 2021, 215: 111318.

2020年发表论文：

1. Zhang JZ, Zhang ZL, Jiang M, Li SH, Yuan HL, Sun HB, Yang F*, Liang H*. Developing a novel gold(III) agent to treat glioma based onthe unique properties of apoferritin nanoparticles: inducing lethal autophagyand apoptosis. Journal of Medicinal Chemistry, 2020, 63: 13695−13708.

2. Zhang ZL, Zhang JZ, Jiang M, Zhao L, Li SH, Sun HB, Yang F*, Liang H*. Human serum albumin-based dual-agent delivery systems for combination therapy: acting against cancer cells and inhibiting neovascularization in the tumor microenvironment. Molecular Pharmaceutics, 2020, 17: 1405−1414. 

3. Li SH, Khan MH, Wang XJ, Cai ML, Zhang JZ, Jiang M, Zhang ZL, Wen XA, Liang H, Yang F*. Synthesis of a series of novel In(III) 2,6-diacetylpyridine bis(thiosemicarbazide) complexes: structure, anticancer function and mechanism. Dalton Transactions, 2020, 49: 17207−17220.

2019年发表论文：

1. Zhang ZL, Yu P, Gou Y, Zhang JZ, Li SH, Cai ML, Sun HB, Yang F*, Liang H*. Novel brain-tumor-inhibiting copper(II) compound based on a human serum albumin (HSA)-cell penetrating peptide conjugate. Journal of Medicinal Chemistry, 2019, 62: 10630−10644.

2. Khan MH, Cai ML, Li SH, Zhang ZL, Zhang JZ, Wen XA, Sun HB*, Liang H, Yang F*. Developing a binuclear multi-target Bi(III) complex by optimizing 2-acetyl-3-ethylpyrazine thiosemicarbazides. European Journal of Medicinal Chemistry, 2019, 182: 111616.

3. Gu SS, Yu P, Hu JN, Liu YN, Li ZW, Qian Y, Wang Y, Gou Y*, Yang F*. Mitochondria-localizing N-heterocyclic thiosemicarbazone copper complexes with good cytotoxicity and high antimetastatic activity. European Journal of Medicinal Chemistry, 2019, 164: 654−664. 

4. Yu P, Deng JG, Cai JH, Zhang ZL, Zhang JZ, Khan MH, Liang H*, Yang F*. Anticancer and biological properties of a Zn-2,6-diacetylpyridine bis(thiosemicarbazone) complex. Metallomics, 2019, 11, 1372−1386.

5. Deng JG, Yu P, Zhang ZL, Zhang JZ, Zhewen S, Cai ML, Yuan HL, Liang H*, Yang F*. Novel Pt(ii) complexes with modified aroyl-hydrazone schiff-base ligands: synthesis, cytotoxicity and action mechanism. Metallomics, 2019, 11: 1847−1863.

6. Khan MH, Cai ML, Deng JG, Yu P, Liang H*, Yang F*. Anticancer function and ROS-mediated multi-targeting anticancer mechanisms of copper (II) 2-hydroxy-1-naphthaldehyde complexes. Molecules. 2019, 24: 2544.

2018年发表论文：

1. Deng JG, Yu P, Zhang ZL, Wang J, Cai JH, Wu N, Sun HB, Liang H*, Yang F*. Designing anticancer copper(II) complexes by optimizing 2-pyridine-thiosemicarbazone ligands. European Journal of Medicinal Chemistry, 2018, 158: 442−452.

2. Mo QY, Deng JG, Liu YN, Huang GD, Li ZW, Yu P, Gou Y*, Yang F*. Mixed-ligand Cu(II) hydrazone complexes designed to enhance anticancer activity. European Journal of Medicinal Chemistry, 2018, 156: 368−380.

3. Gou Y, Zhang ZL, Li DY, Zhao L, Cai ML, Sun ZW, Li YP, Zhang Y, Khan H, Sun HB, Wang T*, Liang H*, Yang F*. HSA-based multi-target combination therapy: regulating drugs' release from HSA and overcoming single drug resistance in a breast cancer model. Drug Delivery, 2018, 25: 321−329. 

4. Wang J, Gou Y, Zhang ZL, Yu P, Qi JX, Qin QP, Sun HB, Wu XY, Liang H*, Yang F*. Developing an anticancer copper(II) multitarget pro-drug based on the His146 residue in the IB subdomain of modified human serum albumin. Molecular Pharmaceutics, 2018, 15: 2180−2193.

5. Deng JG, Wang J, Khan MH, Yu P, Yang F*, Liang H*. Structure and biological properties of five Pt(II) complexes as potential anticancer agents. Journal of Inorganic Biochemistry, 2018, 185: 10−16.

6. Yang F, Liang H*. Designing anticancer multitarget metal thiosemicarbazone prodrug based on the nature of binding sites of human serum albumin carrier. Future Medicinal Chemistry, 2018, 10: 1881−1883. 

2017年发表论文：
1. Ma YL, Yue JP, Zhang Y, Shi CZ, Odenwald M, Liang WG, Wei Q, Goel A, Gou XW, Zhang J, Chen SY, Tang WJ, Turner JR, Yang F*, Liang H*, Qin HL*, Wu XY*. ACF7 regulates inflammatory colitis and intestinal wound response by orchestrating tight junction dynamics. Nature Communications, 2017, 8: 15375.

2. Gou Y*, Li JL, Fan BY, Xu BH, Zhou M, Yang F*. Structure and biological properties of mixed-ligand Cu(II) Schiff base complexes as potential anticancer agents. European Journal of Medicinal Chemistry, 2017, 134: 207−217.

3. Gou Y, Zhang Y, Zhang ZL, Wang J, Zhou ZP, Liang H*, Yang F*. Design of an anticancer copper(II) prodrug based on the Lys199 residue of the active targeting human serum albumin nanoparticle carrier. Molecular Pharmaceutics, 2017, 14: 1861−1873.

4. Zhang Y, Zhang ZL, Gou Y, Jiang M, Khan H, Zhou ZP*, Liang H*, Yang F*. Design an anticancer copper(II) pro-drug based on the flexible IIA subdomain of human serum albumin. Journal of Inorganic Biochemistry, 2017, 172: 1−8.

2016年发表论文：

1. Yue JP, Zhang Y, Liang WG, Gou XW, Lee P, Liu H, Lyv WQ, Tang WJ, Yang F*, Liang H*, Wu XY*. In vivo epidermal migration requires focal adhesion targeting of ACF7. Nature Communications. 2016, 7: 11692.

2. Qi JX, Gou Y, Zhang Y, Yang K, Chen SF, Liu L, Wu XY, Wang T*, Zhang W*, Yang F*. Developing anticancer ferric prodrugs based on the N-donor residues of human serum albumin carrier IIA subdomain. Journal of Medicinal Chemistry, 2016, 59: 7497−7511.

3. Zhang ZL, Gou Y, Wang J, Yang K, Qi JX, Zhou ZP, Liang SC*, Liang H*, Yang F*. Four copper(II) compounds synthesized by anion regulation: Structure, anticancer function and anticancer mechanism. European Journal of Medicinal Chemistry, 2016, 121: 399−409.

4. Gou Y, Wang J, Chen SF, Zhang Z, Zhang Y, Zhang W, Yang F*. a-N-heterocyclic thiosemicarbazone Fe(III) complex: Characterization of its antitumor activity and identification of anticancer mechanism. European Journal of Medicinal Chemistry, 2016, 123: 354−364.

5. Qi JX, Zhang Y, Gou Y, Zhang ZL, Zhou ZP, Wu XY, Yang F*, Liang H*. Developing an anticancer copper(II) pro-drug based on the His242 residue of the human serum albumin carrier IIA subdomain. Molecular Pharmaceutics, 2016, 13: 1501−1507. 

6. Qi JX, Zhang Y, Gou Y, Lee P, Wang J, Chen SF, Zhou ZP, Wu XY, Yang F*, Liang H. Multidrug delivery systems based on human serum albumin for combination therapy with three anticancer agents. Molecular Pharmaceutics, 2016, 13: 3098−3105.

7. Gou Y, Yang F*, Liang H*. Designing prodrugs based on special residues of human serum albumin. Current Topics in Medicinal Chemistry, 2016, 16: 996−1008.

8. Yang F*, Liang H. HSA IIA subdomain-based developing anticancer metal prodrug: a new and improved approach. Future Medicinal Chemistry, 2016, 8: 89−91.

9. Gou Y, Zhang Y, Qi JX, Chen SF, Zhou ZP, Wu XY, Liang H*, Yang F*. Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer. Oncotarget, 2016, 7: 67004−67019.

2015年发表论文：

1. Qi JX, Liang SC, Gou Y, Zhang Z, Zhou ZL, Yang F*, Liang H*. Synthesis of four binuclear copper(II) complexes: Structure, anticancer properties and anticancer mechanism. European Journal of Medicinal Chemistry, 2015, 96: 360−368.

2. Gou Y, Qi JX, Ajayi JP, Zhang Y, Zhou ZP, Wu XY, Yang F*, Liang H*. Developing anticancer copper(II) pro-drugs based on the nature of cancer cells and the human serum albumin carrier IIA subdomain. Molecular Pharmaceutics, 2015, 12: 3597−3609.

3. Gou Y, Zhang Z, Qi JX, Liang SC, Zhou ZP, Yang F*, Liang H*. Folate-functionalized human serum albumin carrier for anticancer copper(II) complexes derived from natural plumbagin. Journal of Inorganic Biochemistry, 2015, 153: 13−22.

4. Gou Y, Zhang Y, Qi JX, Zhou ZP, Yang F*, Liang H*. Enhancing the copper(II) complexes cytotoxicity to cancer cells through bound to human serum albumin. Journal of Inorganic Biochemistry, 2015, 144: 47−55.

5. Gou Y, Zhang Y, Yang F*, Liang H*. Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugs. Current Pharmaceutical Design, 2015, 21: 1848−1861.

6. Zhang Y, Lee P, Liang SC, Zhou ZP, Wu XY, Yang F*, Liang H*. Structural basis of non-steroidal anti-inflammatory drug diclofenac binding to human serum albumin. Chemical Biology & Drug Design, 2015, 86: 1178−1184.

7. Gou Y, Zhang Y, Qi J, Kong L, Zhou Z, Liang S, Yang F*, Liang H*. Binding and anticancer properties of plumbagin with human serum albumin. Chemical Biology & Drug Design, 2015, 86: 362−369.

2014年发表论文：

1. Zhang Y, Ho A, Yue JP, Kong LL, Zhou ZP, Wu XY, Yang F*, Liang H*. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin. European Journal of Medicinal Chemistry, 2014, 86: 449−455.

2. Li M, McAuley E, Zhang Y, Kong LL, Yang F*, Zhou ZP, Wu XY, Liang H*. Comparison of binding characterization of two antiviral drugs to human serum albumin. Chemical Biology & Drug Design, 2014, 83: 576−582.

3. Li M, Lee P, Zhang Y, Ma ZY, Yang F*, Zhou ZP, Wu XY, Liang H*. X-ray crystallographic and fluorometric analysis of the interactions of rhein to human serum albumin. Chemical Biology & Drug Design, 2014, 83: 167−173.

4. Liang H*, Yang F, Lee N, Wu XY. HSA-based anti-inflammatory therapy: a new and improved approach. Future Medicinal Chemistry, 2014, 6: 119−121.

5. Yang F*, Zhang Y, Liang H*. Interactive association of drugs binding to human serum albumin. International Journal of Molecular Sciences,  2014, 15: 3580−3595.

6. Li M, Kong LL, Gou Y, Yang F*, Liang H*. DNA binding, cytotoxicity and apoptosis induction activity of a mixed-ligand copper(II) complex with taurine Schiff base and imidazole. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2014, 128: 686−693.

2013年以前发表论文：

1. Yang F, Ma ZY, Zhang Y, Li GQ, Li M, Qin JK, Lockridge O, Liang H*. Human serum albumin-based design of a diflunisal prodrug. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84: 549−554. 

2. Yang F, Lee P, Ma ZY, Ma L, Yang GP, Wu XY, Liang H*. Regulation of amantadine hydrochloride binding with IIA subdomain of human serum albumin by fatty acid chains. Journal of Pharmaceutical Sciences, 2013, 102: 84−92. 

3. Li M, Gou Y, Zhang Y, Yang F*, Liang H*. Synthesis, structure, protein binding, and cytotoxicity of zinc(II) complexes with tridentate NNO Schiff-base ligands. Journal of Coordination Chemistry, 2014, 67: 929–942.

4. Yang F, Yue J, Ma L, Ma Z, Li M, Wu X, Liang H*. Interactive associations of drug-drug and drug-drug-drug with IIA subdomain of human serum albumin. Molecular Pharmaceutics, 2012, 9: 3259–3265.